Low-Molecular-Weight Heparin (LMWH) for Deep Venous Thrombosis (DVT) Prophylaxis

University of Tennessee logo

University of Tennessee

Status

Unknown

Conditions

Deep Venous Thrombosis

Treatments

Drug: Low-Molecular-Weight Heparin

Study type

Interventional

Funder types

Other

Identifiers

NCT01029821
Pugh-2

Details and patient eligibility

About

1. The use of LMWH following open reduction and internal fixation of ankle fractures will reduce the number of thrombi formed. 2. The rates of clinically significant DVT will be equivalent between two groups.

Full description

Routine use of thromboprophylaxis may be over treatment and definitely increases healthcare costs. While prophylaxis may reduce the number of thrombi formed the exact number and clinical significance of these is unknown. This study seeks to answer the question of whether or not DVT prophylaxis with low-molecular-weight heparin (LMWH) following ORIF of ankle fractures is warranted.

Enrollment

100 estimated patients

Sex

All

Ages

18 to 85 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

* At least 18 years old * Surgical ankle fracture able to be definitively treated with one operation

Exclusion criteria

* Younger than 18 years of age * Other significant injury * Known hypercoagulable state * History of bleeding disorder * History of DVT

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

100 participants in 1 patient group

Low-Molecular-Weight Heparin for DVT
Other group
Description:
Low-Molecular-Weight Heparin for DVT Prophylaxis after Open Reduction and Internal Fixation of ankle fractures
Treatment:
Drug: Low-Molecular-Weight Heparin

Trial contacts and locations

1

Loading...

Central trial contact

Stan Ragon, M.D.; Elaine Pugh

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems